Company / Revenue per Share
TherapeuticsMD, Inc. Revenue per Share History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$0.11
FY2024
5-year range
$0.06 / $7.37
FY2020-FY2024
Trend
-98.5%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue per Share has fluctuated over the past 10 years, ranging from $0.06 in FY2020 to $7.37 in FY2023.
Based on SEC 10-K filings.
0.11 in FY2024 with a 5-year CAGR of +10.1%.
Declined from $0.30 to $0.11 over the past 2 years.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- -12.0%
- 5-Year CAGR
- +10.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, revenue per share decreased 98.5% year-over-year.
- Peak revenue per share was recorded in FY2023.
- Lowest revenue per share in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $0.11 | -98.5% |
| FY2023 | $7.37 | +2361.5% |
| FY2022 | $0.30 | +80.7% |
| FY2021 | $0.17 | +179.0% |
| FY2020 | $0.06 | -14.9% |
| FY2019 | $0.07 | -22.0% |
| FY2018 | $0.09 | -12.7% |
| FY2017 | $0.10 | +21.3% |
| FY2016 | $0.08 | +39.5% |
| FY2015 | $0.06 | +129.8% |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026